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Table 1. C-reactive protein levels in hemodialyzed patients with or
without coronary heart disease
CHD+ CHD−
Number 11 17
Mean ± SD 9.0 ± 7.4 10.3 ± 10.6
Range 3.2 – 27.1 3.2 – 37.7
P vs CHD− 0.725
Abbreviations: CHD+, hemodialysis patients with coronary heart disease;
CHD−, hemodialysis patients without coronary heart disease. C-reactive protein
levels are expressed as mg per L.
levels were 72.0 and 3.2 mg per L, respectively, and the
patient with highest level had also chest infection. We
still believe that CRP is a good inflammatory marker, but
the emerging opinion that CRP is also a sensitive marker
for myocardial infarction should be revisited using the
current methods of the evidence-based medicine.
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Combination therapy with
ACE inhibitors and
angiotensin II receptor
blockers in chronic renal
disease: New therapeutic
world beyond blood pressure
reduction
To the Editor: We read the recent article by Wolf et al
comprehensively reviewing pathophysiology and indica-
tion of combination therapy with angiotensin-converting
enzyme (ACE) inhibitors and angiotensin II receptor
blockers in chronic renal disease [1]. As one author of the
COOPERATE study, I would like to comment on several
issues quoted by them. First, because the COOPERATE
study was the fixed dose-design, during a run-in period,
the dose of trandolapril had been adjusted to reach a max-
imal reduction in proteinuria, but not in blood pressure
(BP). We had noticed that the maximally licensed dose
of trandolapril (up to 2 mg/day) was not sufficient to re-
duce proteinuria maximally, which required 3 mg daily.
Therefore, we determined 3 mg of trandolapril in the core
COOPERATE study [2]. Second, as Wolf et al specu-
lated, 24-hour BP might be different among 3 groups.
In this issue, we have recently published the results of
the COOPERATE-ABP substudy [3]. In this substudy,
92 patients enrolled in the COOPERATE trial under-
went 24-hour ambulatory blood pressure (ABP) moni-
toring at randomization and at month 6, year 1, year 2,
and year 3 on randomized treatment. Both office blood
pressure (OPB) and ABP were similarly reduced among
3 groups at all measurement points and throughout the
whole study period. No significant correlation between
the change in 24-hour ABP and the change in protein-
uria was seen. Therefore, ABPM did not seem to have
any benefits over OBP. Third, the study agents were ad-
ministrated 3 times a day, and the dose on each arm
was gradually and carefully up-titrated (Fig. 1). There-
fore, it seems unlikely that a difference at the time of
peak actions of the agents might be attributable to the
superior antiproteinuric effect in the combination ther-
apy. The COOPERATE-ABP substudy did not detect
any difference of daily BP profile [3]. Last, both OBP
and ABP were not selected as a significant risk factor in
Cox-multivariable model for renal survival [2, 3]. In con-
clusion, combination therapy with ACE inhibitors and
angiotensin II receptor blockers can halt progression of
chronic renal disease beyond BP reduction.
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Fig. 1. Dose-escalating schedule of trandolapril, losartan, and combination of two agents in the COOPERATE study.
